Literature DB >> 33539595

Diabetes and atrial fibrillation in hospitalized patients in the United States.

Nilay Kumar1, Justin B Echouffo-Tcheugui2.   

Abstract

BACKGROUND: Data on the burden of atrial fibrillation (AF) associated with diabetes among hospitalized patients are scarce. We assessed the AF-related hospitalizations trends in patients with diabetes, and compared AF outcomes in patients with diabetes to those without diabetes. HYPOTHESIS: AF-related health outcomes differ between patient with diabetes and without diabetes.
METHODS: Using the National Inpatient Sample (NIS) 2004-2014, we studied trends in AF hospitalization rate among diabetic patients, and compared in-hospital case fatality rate, length of stay (LOS), cost and utilization of rhythm control therapies, and 30-day readmission rate between patients with and without diabetes. Logistic or Cox regression models were used to assess the differences in AF outcomes by diabetes status.
RESULTS: Over the study period, there were 4 325 522 AF-related hospitalizations, of which 1 075 770 (24.9%) had a diagnosis of diabetes. There was a temporal increase in AF hospitalization rate among diabetic patients (10.4 to 14.4 per 1000 hospitalizations among patients with diabetes; +4.4% yearly change, p-trend < .0001). Among AF patients, those with diabetes had a lower in-hospital mortality (adjusted odds ratio [aOR]: 0.68; 95% CI: 0.65-0.72) and LOS (aOR: 0.95; 95% CI: 0.94-0.96), but no difference in costs (aOR: 0.95; 95% CI: 0.94-0.96) and a higher 30-day rate of readmissions compared with no diabetes (aHR 1.05; 95% CI: 1.01-1.08), compared to individuals without diabetes.
CONCLUSION: AF and diabetes coexist among hospitalized patients, with rising trends over the last decade. Diabetes is associated with lower rates in-hospital adverse AF outcomes, but a higher 30-day readmission risk.
© 2021 The Authors. Clinical Cardiology published by Wiley Periodicals LLC.

Entities:  

Keywords:  atrial fibrillation; diabetes mellitus; trends

Mesh:

Year:  2021        PMID: 33539595      PMCID: PMC7943913          DOI: 10.1002/clc.23533

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   3.287


  27 in total

1.  Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide Cohort Study.

Authors:  Thure Filskov Overvad; Flemming Skjøth; Gregory Y H Lip; Deirdre A Lane; Ida Ehlers Albertsen; Lars Hvilsted Rasmussen; Torben Bjerregaard Larsen
Journal:  Stroke       Date:  2015-07-07       Impact factor: 7.914

2.  Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

Authors:  Benjamin A Steinberg; Sunghee Kim; Gregg C Fonarow; Laine Thomas; Jack Ansell; Peter R Kowey; Kenneth W Mahaffey; Bernard J Gersh; Elaine Hylek; Gerald Naccarelli; Alan S Go; James Reiffel; Paul Chang; Eric D Peterson; Jonathan P Piccini
Journal:  Am Heart J       Date:  2014-02-17       Impact factor: 4.749

Review 3.  Meta-analysis of cohort and case-control studies of type 2 diabetes mellitus and risk of atrial fibrillation.

Authors:  Rachel R Huxley; Kristian B Filion; Suma Konety; Alvaro Alonso
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

4.  Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning.

Authors:  Nileshkumar J Patel; Abhishek Deshmukh; Sadip Pant; Vikas Singh; Nilay Patel; Shilpkumar Arora; Neeraj Shah; Ankit Chothani; Ghanshyambhai T Savani; Kathan Mehta; Valay Parikh; Ankit Rathod; Apurva O Badheka; James Lafferty; Marcin Kowalski; Jawahar L Mehta; Raul D Mitrani; Juan F Viles-Gonzalez; Hakan Paydak
Journal:  Circulation       Date:  2014-05-19       Impact factor: 29.690

5.  Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States.

Authors:  Karin S Coyne; Clark Paramore; Susan Grandy; Marco Mercader; Matthew Reynolds; Peter Zimetbaum
Journal:  Value Health       Date:  2006 Sep-Oct       Impact factor: 5.725

6.  Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: A cohort study.

Authors:  W Saliba; O Barnett-Griness; M Elias; G Rennert
Journal:  Heart Rhythm       Date:  2015-01-19       Impact factor: 6.343

7.  Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry.

Authors:  Justin B Echouffo-Tcheugui; Peter Shrader; Laine Thomas; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Daniel E Singer; Elaine M Hylek; Alan S Go; Eric D Peterson; Jonathan P Piccini; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2017-09-12       Impact factor: 24.094

8.  Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012.

Authors:  Andy Menke; Sarah Casagrande; Linda Geiss; Catherine C Cowie
Journal:  JAMA       Date:  2015-09-08       Impact factor: 56.272

9.  Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study.

Authors:  So-Ryoung Lee; Eue-Keun Choi; Kyung-Do Han; Myung-Jin Cha; Seil Oh; Gregory Y H Lip
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

10.  Diabetes and atrial fibrillation in hospitalized patients in the United States.

Authors:  Nilay Kumar; Justin B Echouffo-Tcheugui
Journal:  Clin Cardiol       Date:  2021-02-04       Impact factor: 3.287

View more
  3 in total

Review 1.  [Rhythm and metabolic control].

Authors:  Denise Guckel; Christian Sohns; Philipp Sommer
Journal:  Herz       Date:  2022-07-18       Impact factor: 1.740

2.  Diabetes and atrial fibrillation in hospitalized patients in the United States.

Authors:  Nilay Kumar; Justin B Echouffo-Tcheugui
Journal:  Clin Cardiol       Date:  2021-02-04       Impact factor: 3.287

Review 3.  Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation.

Authors:  Andreas S Papazoglou; Anastasios Kartas; Dimitrios V Moysidis; Christos Tsagkaris; Stavros P Papadakos; Alexandra Bekiaridou; Athanasios Samaras; Efstratios Karagiannidis; Marios Papadakis; George Giannakoulas
Journal:  Cardiovasc Diabetol       Date:  2022-03-14       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.